Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitisThomas Werfel, Lynn Purkins, Aliya Asher et al.|Journal of Allergy and Clinical Immunology|2018Cited by 136
Effect of omeprazole on the steady‐state pharmacokinetics of voriconazoleNolan Wood, D. J. Nichols, Keith Tan et al.|British Journal of Clinical Pharmacology|2003Cited by 105
No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteersLynn Purkins, D. J. Nichols, Nolan Wood et al.|British Journal of Clinical Pharmacology|2003Cited by 34
A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389) a potent, oral histamine H4, receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adultsThomas Werfel, W. Liu, Victoria Lynch et al.|Open Repository and Bibliography (University of Liège)|2016Cited by 15